Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Construction and validation of a risk prediction model for clinical axillary lymph node metastasis in T1-2 breast cancer.

Tytuł:
Construction and validation of a risk prediction model for clinical axillary lymph node metastasis in T1-2 breast cancer.
Autorzy:
Luo N; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.; Department of General Surgery, The First People's Hospital of Changde City, Changde, China.
Wen Y; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Zou Q; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ouyang D; Department of General Surgery, Xiangya Hospital Central South University, Changsha, China.
Chen Q; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Zeng L; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
He H; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Anwar M; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Qu L; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ji J; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. .
Yi W; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. .
Źródło:
Scientific reports [Sci Rep] 2022 Jan 13; Vol. 12 (1), pp. 687. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Axilla*
Models, Theoretical*
Breast Neoplasms/*pathology
Lymphatic Metastasis/*diagnosis
Area Under Curve ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Female ; Forecasting ; Humans ; Logistic Models ; Lymphatic Metastasis/genetics ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; RNA, Messenger ; Receptor, ErbB-2 ; Risk
References:
Siegel, R. L. et al. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021). (PMID: 3343394610.3322/caac.21654)
Chang, C. C. et al. Prognostic significance of metabolic parameters and textural features on (18)F-FDG PET/CT in invasive ductal carcinoma of breast. Sci. Rep. 9, 10946 (2019). (PMID: 31358786666279210.1038/s41598-019-46813-5)
Krag, D. N. et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8, 881–888 (2007). (PMID: 1785113010.1016/S1470-2045(07)70278-4)
Di Filippo, F. et al. Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method. J. Exp. Clin. Cancer Res. 34, 136 (2015). (PMID: 26538019463227610.1186/s13046-015-0246-2)
Gradishar, W. J. et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl. Comp. Cancer Netw. 18, 452–478 (2020). (PMID: 10.6004/jnccn.2020.0016)
Schipper, R. J. et al. Axillary ultrasound for preoperative nodal staging in breast cancer patients: Is it of added value?. Breast 22, 1108–1113 (2013). (PMID: 2409561110.1016/j.breast.2013.09.002)
Majid, S., Tengrup, I. & Manjer, J. Clinical assessment of axillary lymph nodes and tumor size in breast cancer compared with histopathological examination: A population-based analysis of 2,537 women. World J. Surg. 37, 67–71 (2013). (PMID: 2297679310.1007/s00268-012-1788-5)
Shien, T. et al. Evaluation of axillary status in patients with breast cancer using thin-section CT. Int. J. Clin. Oncol. 13, 314–319 (2008). (PMID: 1870463110.1007/s10147-007-0753-z)
Shan, Y. N. et al. A nomogram combined radiomics and kinetic curve pattern as imaging biomarker for detecting metastatic axillary lymph node in invasive breast cancer. Front. Oncol. 10, 1463 (2020). (PMID: 32983979748354510.3389/fonc.2020.01463)
Gao, Y. et al. Nomogram based on radiomics analysis of primary breast cancer ultrasound images: Prediction of axillary lymph node tumor burden in patients. Eur. Radiol. 31, 928–937 (2021). (PMID: 3284538810.1007/s00330-020-07181-1)
Xie, X. et al. Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int. J. Cancer 142, 1901–1910 (2018). (PMID: 2922633210.1002/ijc.31208)
Zhang, N. et al. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen. Cancer Lett. 498, 54–69 (2021). (PMID: 3306977010.1016/j.canlet.2020.10.019)
Li, Y. et al. OSR1 phosphorylates the Smad2/3 linker region and induces TGF-β1 autocrine to promote EMT and metastasis in breast cancer. Oncogene 40, 68–84 (2021). (PMID: 3305159710.1038/s41388-020-01499-2)
Lone, B. A. et al. SUPT5H post-transcriptional silencing modulates PIN1 expression, inhibits tumorigenicity, and induces apoptosis of human breast cancer cells. Cell. Physiol. Biochem. 54, 928–946 (2020). (PMID: 3296104410.33594/000000279)
Min, Y. et al. Tubular carcinoma of the breast: Clinicopathologic features and survival outcome compared with ductal carcinoma in situ. J. Breast Cancer 16, 404–409 (2013). (PMID: 24454462389334210.4048/jbc.2013.16.4.404)
Vickers, A. J. et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform. Decis. Mak. 8, 53 (2008). (PMID: 19036144261197510.1186/1472-6947-8-53)
Guo, H. et al. Prognostic values of a novel multi-mRNA signature for predicting relapse of cholangiocarcinoma. Int. J. Biol. Sci. 16, 869–881 (2020). (PMID: 32071556701914410.7150/ijbs.38846)
Györffy B.,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast cancer research and treatment 123, 725–31 (2010). (PMID: 2002019710.1007/s10549-009-0674-9)
Miao, Y. R. et al. ImmuCellAI: A unique method for comprehensive t-cell subsets abundance prediction and its application in cancer immunotherapy. Adv. Sci. 7, 1902880 (2020). (PMID: 10.1002/advs.201902880)
Newman A. M., et al. Robust enumeration of cell subsets from tissue expression profiles.Nature methods 12, 453–7 (2015). (PMID: 25822800473964010.1038/nmeth.3337)
Li T., et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic acids research 48, W509–w14 (2020). (PMID: 32442275731957510.1093/nar/gkaa407)
Yuan, C. et al. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci. Rep. 9, 14356 (2019). (PMID: 31591439677989310.1038/s41598-019-50898-3)
Suman, P., Mishra, S. & Chander, H. High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas. Sci. Rep. 10, 11543 (2020). (PMID: 32665637736056810.1038/s41598-020-68454-9)
Alba, A. C. et al. Discrimination and calibration of clinical prediction models: Users’ guides to the medical literature. JAMA 318, 1377–1384 (2017). (PMID: 2904959010.1001/jama.2017.12126)
Jung, Y. Y., Kim, H. M. & Koo, J. S. Expression of lipid metabolism-related proteins in metastatic breast cancer. PLoS ONE 10, e0137204 (2015). (PMID: 26334757455931210.1371/journal.pone.0137204)
La Rocca, G. et al. CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. Histopathology 52, 203–212 (2008). (PMID: 1818426910.1111/j.1365-2559.2007.02919.x)
Miyakoshi, H. et al. 1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors. J. Med. Chem. 55, 6427–6437 (2012). (PMID: 2271597310.1021/jm3004174)
Jiang, F. N. et al. Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer. Pathol. Res. Pract. 216, 152732 (2020). (PMID: 3178005510.1016/j.prp.2019.152732)
Chang, Y. S. et al. Pathway mutations in breast cancer using whole-exome sequencing. Oncol. Res. 28, 107–116 (2020). (PMID: 31575382785157410.3727/096504019X15698362825407)
Zhu, L. et al. Loss of HOXB3 correlates with the development of hormone receptor negative breast cancer. PeerJ 8, e10421 (2020). (PMID: 33240685768243410.7717/peerj.10421)
Altemus, M. A. et al. Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes. PLoS ONE 14, e0220973 (2019). (PMID: 31536495675286810.1371/journal.pone.0220973)
Shi, L., Huang, R. & Lai, Y. Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia. BMC Med. Genomics 14, 127 (2021). (PMID: 33985510812081510.1186/s12920-021-00975-2)
Zorniak, M. et al. Differential expression of 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival. Clin. Cancer Res. 18, 3628–3636 (2012). (PMID: 22589395359746910.1158/1078-0432.CCR-12-0339)
Xu, C. et al. Expression of OPN3 in lung adenocarcinoma promotes epithelial-mesenchymal transition and tumor metastasis. Thoracic Cancer 11, 286–294 (2020). (PMID: 3180264310.1111/1759-7714.13254)
Drecourt, A. et al. Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 102, 266–277 (2018). (PMID: 29395073598545110.1016/j.ajhg.2018.01.003)
Maimaiti, A. et al. Integrated gene expression and methylation analyses identify DLL3 as a biomarker for prognosis of malignant glioma. J. Mol. Neurosci. 71, 1622–1635 (2021). (PMID: 3371332010.1007/s12031-021-01817-7)
Inamura, K. et al. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. Anticancer Res. 28, 2121–2127 (2008). (PMID: 18751384)
He, Q. et al. Homeobox B5 promotes metastasis and poor prognosis in hepatocellular carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics 11, 5759–5777 (2021). (PMID: 33897880805872110.7150/thno.57659)
Huo, X. Y. et al. HOXB7 promotes proliferation and metastasis of glioma by regulating the Wnt/β-catenin pathway. Eur. Rev. Med. Pharmacol. Sci. 25, 3146 (2021). (PMID: 33928593)
Srour, M. K. et al. Gene expression comparison between primary triple-negative breast cancer and paired axillary and sentinel lymph node metastasis. Breast J. 26, 904–910 (2020). (PMID: 3171329810.1111/tbj.13684)
Ding, Y. L., Sun, S. F. & Zhao, G. L. COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis. Medicine 100, e24561 (2021). (PMID: 33607786789983510.1097/MD.0000000000024561)
Zhang, J., Hu, S. & Li, Y. KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer. Biosci. Rep. 39, 8 (2019).
Wang, X. et al. BRAF(V600E)-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT. Oncol. Lett. 18, 927–935 (2019). (PMID: 312895716539636)
Arole, V. et al. M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma. Breast Cancer Res. Treat. 188, 37–42 (2021). (PMID: 3403298610.1007/s10549-021-06260-1)
Tashireva, L. A. et al. Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis. Immunobiology 222, 631–640 (2017). (PMID: 2791628110.1016/j.imbio.2016.11.012)
Grant Information:
2020JJ4828 Natural Science Foundation of Hunan Province; 2021SK2026 the science and technology innovation Program of Hunan Province
Substance Nomenclature:
0 (RNA, Messenger)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
Entry Date(s):
Date Created: 20220114 Date Completed: 20220228 Latest Revision: 20221025
Update Code:
20240104
PubMed Central ID:
PMC8758717
DOI:
10.1038/s41598-021-04495-y
PMID:
35027588
Czasopismo naukowe
The current diagnostic technologies for assessing the axillary lymph node metastasis (ALNM) status accurately in breast cancer (BC) remain unsatisfactory. Here, we developed a diagnostic model for evaluating the ALNM status using a combination of mRNAs and the T stage of the primary tumor as a novel biomarker. We collected relevant information on T1-2 BC from public databases. An ALNM prediction model was developed by logistic regression based on the screened signatures and then internally and externally validated. Calibration curves and the area under the curve (AUC) were employed as performance metrics. The prognostic value and tumor immune infiltration of the model were also determined. An optimal diagnostic model was created using a combination of 11 mRNAs and T stage of the primary tumor and showed high discrimination, with AUCs of 0.828 and 0.746 in the training sets. AUCs of 0.671 and 0.783 were achieved in the internal validation cohorts. The mean external AUC value was 0.686 and ranged between 0.644 and 0.742. Moreover, the new model has good specificity in T1 and hormone receptor-negative/human epidermal growth factor receptor 2- negative (HR-/HER2-) BC and good sensitivity in T2 BC. In addition, the risk of ALNM and 11 mRNAs were correlated with the infiltration of M2 macrophages, as well as the prognosis of BC. This novel prediction model is a useful tool to identify the risk of ALNM in T1-2 BC patients, particularly given that it can be used to adjust surgical options in the future.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies